The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...

Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.

Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's ...

JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...

Alnylam (ALNY) announced the FDA approval of the supplemental New Drug Application for its RNAi therapeutic, Amvuttra, for the treatment of the ...